OpenAI acquires Orchestra Bio to build out life-sciences AI

· Tech · United States

OpenAI is acquiring Orchestra Bio, a startup that builds AI agents to help biotech and pharmaceutical companies with drug development, the AI lab announced on Tuesday. OpenAI said it will add Orchestra's team and technology to work on Rosalind, its AI model for life-sciences research, and on Rosalind Workbench, a tool meant to help researchers plan experiments and analyze results. The acquisition is an early move toward a goal OpenAI executives have long touted: using the company's technology to assist drug discovery and development. Terms of the deal were not disclosed in the reports.

Why it matters：Model developers are moving from selling APIs into owning domain-specific workflows, putting them in more direct competition with the software vendors and CROs that serve pharma.

Key points

  • Orchestra builds AI agents for drug development at biotech and pharma firms
  • Its team and tech will feed Rosalind and Rosalind Workbench
  • Deal terms were not disclosed

Sources (original reporting)

More stories from this day